Triple Negative Breast Cancer — Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Citation(s)
Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA